CryoEM structure of adenovirus type 3 fibre with desmoglein 2 shows an unusual mode of receptor engagement.
Adenoviridae Infections
/ pathology
Adenoviruses, Human
/ metabolism
Asparagine
/ genetics
Capsid Proteins
/ metabolism
Cryoelectron Microscopy
Desmoglein 2
/ metabolism
HEK293 Cells
Humans
Models, Molecular
Protein Domains
Receptors, Virus
/ metabolism
Recombinant Proteins
/ metabolism
Virus Attachment
Journal
Nature communications
ISSN: 2041-1723
Titre abrégé: Nat Commun
Pays: England
ID NLM: 101528555
Informations de publication
Date de publication:
12 03 2019
12 03 2019
Historique:
received:
05
11
2018
accepted:
26
02
2019
entrez:
14
3
2019
pubmed:
14
3
2019
medline:
6
4
2019
Statut:
epublish
Résumé
Attachment of human adenovirus (HAd) to the host cell is a critical step of infection. Initial attachment occurs via the adenoviral fibre knob protein and a cellular receptor. Here we report the cryo-electron microscopy (cryo-EM) structure of a <100 kDa non-symmetrical complex comprising the trimeric HAd type 3 fibre knob (HAd3K) and human desmoglein 2 (DSG2). The structure reveals a unique stoichiometry of 1:1 and 2:1 (DSG2: knob trimer) not previously observed for other HAd-receptor complexes. We demonstrate that mutating Asp261 in the fibre knob is sufficient to totally abolish receptor binding. These data shed new light on adenovirus infection strategies and provide insights for adenoviral vector development and structure-based design.
Identifiants
pubmed: 30862836
doi: 10.1038/s41467-019-09220-y
pii: 10.1038/s41467-019-09220-y
pmc: PMC6414520
doi:
Substances chimiques
Capsid Proteins
0
DSG2 protein, human
0
Desmoglein 2
0
Receptors, Virus
0
Recombinant Proteins
0
hexon capsid protein, Adenovirus
0
Asparagine
7006-34-0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1181Références
Mol Ther Methods Clin Dev. 2015 Mar 11;2:15005
pubmed: 26029716
J Immunother Cancer. 2017 Sep 19;5(1):71
pubmed: 28923104
J Virol. 2011 Jul;85(13):6390-402
pubmed: 21525338
Nat Med. 2003 Nov;9(11):1408-12
pubmed: 14566335
Nat Med. 2011 Jan;17(1):96-104
pubmed: 21151137
J Mol Biol. 2007 Sep 21;372(3):774-97
pubmed: 17681537
PLoS Pathog. 2013 Oct;9(10):e1003718
pubmed: 24204268
Mol Ther Oncolytics. 2017 Mar 29;5:62-74
pubmed: 28480328
J Virol. 2005 Nov;79(22):14429-36
pubmed: 16254377
Protein Sci. 2018 Jan;27(1):293-315
pubmed: 29067766
Elife. 2016 Nov 15;5:
pubmed: 27845625
J Comput Chem. 2004 Oct;25(13):1605-12
pubmed: 15264254
J Virol. 1998 Oct;72(10):7909-15
pubmed: 9733828
J Struct Biol. 2016 Jan;193(1):1-12
pubmed: 26592709
Science. 1999 Nov 19;286(5444):1579-83
pubmed: 10567268
Elife. 2016 Sep 26;5:
pubmed: 27669148
J Virol. 2013 Nov;87(21):11346-62
pubmed: 23946456
Science. 1997 Feb 28;275(5304):1320-3
pubmed: 9036860
Biochem J. 2002 Mar 1;362(Pt 2):317-27
pubmed: 11853539
J Virol. 2010 Apr;84(7):3189-200
pubmed: 20071571
Sci Rep. 2018 May 30;8(1):8381
pubmed: 29849084
Nat Biotechnol. 1997 Jan;15(1):52-6
pubmed: 9035106
Nature. 2007 Dec 6;450(7171):832-7
pubmed: 18064004
J Clin Microbiol. 2010 Apr;48(4):1391-6
pubmed: 20147640
Acta Crystallogr D Biol Crystallogr. 2010 Apr;66(Pt 4):486-501
pubmed: 20383002
Proc Natl Acad Sci U S A. 2016 Jun 28;113(26):7160-5
pubmed: 27298358
Acta Crystallogr D Biol Crystallogr. 2010 Feb;66(Pt 2):213-21
pubmed: 20124702
J Cell Biol. 1997 Jul 14;138(1):193-201
pubmed: 9214392
J Virol. 2012 May;86(9):5380-5
pubmed: 22345476
Am J Epidemiol. 1969 Jan;89(1):25-50
pubmed: 4303049
Cancer Res. 2011 Nov 15;71(22):7080-90
pubmed: 21990319
Nat Struct Mol Biol. 2007 Feb;14(2):164-6
pubmed: 17220899
Virology. 2005 Sep 30;340(2):167-73
pubmed: 16040074
Nat Med. 2011 Jan;17(1):105-9
pubmed: 21151139
Cancer Gene Ther. 2011 Apr;18(4):288-96
pubmed: 21183947
Virol J. 2009 Jan 26;6:11
pubmed: 19171030
Nat Methods. 2017 Apr;14(4):331-332
pubmed: 28250466
J Infect Dis. 2007 Nov 15;196(10):1465-73
pubmed: 18008225
Virology. 2001 Jul 5;285(2):302-12
pubmed: 11437664